Pharmascience Inc., in consultation with Health Canada, is recalling one lot of PMS-Losartan-HCTZ due to a labelling error on the blister pack (see photo below). The printed boxes of the product show the proper dosage “Losartan-HCTZ100/25mg,” while some blisters or inner packages incorrectly say “Losartan-HCTZ 100/12.5mg.” The product is packaged with 100/25mg tablets. Taking more of the drug than prescribed could have serious health effects.
Products affected
PMS-Losartan-HCTZ (Lot number: 0300804).
Who is affected
Canadians who either have used or purchased PMS-Losartan-HCTZ 100/25mg lot number 0300804.
What you should do
If you are taking this product, check the packaging for the lot number. If this is the affected lot, return the product to your pharmacist and obtain a replacement.
Report any adverse events using these products to Health Canada.
Background
PMS-Losartan-HCTZ 100/25mg is a combination product of both losartan (100 mg) and hydrochlorothiazide (HCTZ, 25mg) used for the treatment of hypertension (high blood pressure). One lot is being recalled due to a labelling error on the inner package or blister. Taking two 100/25mg tablets instead of one to obtain the correct amount of HCTZ would result in a double dose of both components (losartan and HCTZ) of this product and potential serious adverse effects. The possible risks of a double dose include hypotension (low blood pressure), fast heart rate, and depletion of electrolytes (or salts) in the body and dehydration.
What Health Canada is doing
Health Canada is monitoring Pharmascience Inc.’s recall and will inform Canadians should there be new information, as necessary.
Report health or safety concerns
Call toll-free at 1-866-234-2345
Visit MedEffect Canada's web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For more information
Consumers and health professionals wanting more information about this advisory from Health Canada can contact the Public Enquiries Line at 613-957-2991, or toll free at 1-866-225-0709.
Media enquiries related to this Advisory should be directed to Health Canada Media Relations at 613-957-2983.